Artelo Biosciences Inc Financials

ARTL

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Artelo Biosciences Inc (ARTL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Artelo Biosciences Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.85x

For every $1 of reported earnings, Artelo Biosciences Inc generates $0.85 in operating cash flow (-$8.3M OCF vs -$9.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$9.8M

YoY-5.8%

Artelo Biosciences Inc reported -$9.8M in net income in fiscal year 2024. This represents a decrease of 5.8% from the prior year.

EPS (Diluted)

$-18.30

YoY+2.7%

Artelo Biosciences Inc earned $-18.30 per diluted share (EPS) in fiscal year 2024. This represents an increase of 2.7% from the prior year.

Cash & Debt

$2.3M

YoY-16.9%

5Y CAGR+47.3%

Artelo Biosciences Inc held $2.3M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

567,582

YoY+6.8%

Artelo Biosciences Inc had 567,582 shares outstanding in fiscal year 2024. This represents an increase of 6.8% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$6.0M

YoY+5.2%

5Y CAGR+36.8%

Artelo Biosciences Inc invested $6.0M in research and development in fiscal year 2024. This represents an increase of 5.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ARTL Income Statement

Metric	FY24	FY23	FY22	FY21	FY19	FY18
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$6.0M+5.2%	$5.7M+31.7%	$4.3M+14.3%	$3.8M+246.5%	$1.1M-12.6%	$1.2M
SG&A Expenses	$4.1M-2.8%	$4.2M-29.0%	$6.0M+5.9%	$5.6M+491.5%	$952K+87.4%	$508K
Operating Income	-$10.1M-1.8%	-$9.9M+3.5%	-$10.3M-9.2%	-$9.4M-193.4%	-$3.2M-37.0%	-$2.3M
Interest Expense	N/A	$0-100.0%	$5K	$0	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$9.8M-5.8%	-$9.3M+7.9%	-$10.1M-7.2%	-$9.4M-333.1%	-$2.2M+7.3%	-$2.3M
EPS (Diluted)	$-18.30+2.7%	$-18.80	N/A	N/A	$-1.46+20.7%	$-1.84

Metric	Q3'25	Q4'23	Q3'24	Q4'22	Q3'23	Q4'21	Q3'22	Q1'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.3M	N/A	$1.6M	N/A	$1.1M-44.5%	$1.9M+88.0%	$1.0M+3.5%	$999K
SG&A Expenses	$1.8M	N/A	$1.0M	N/A	$1.3M-37.3%	$2.1M+73.2%	$1.2M+13.5%	$1.1M
Operating Income	-$3.1M	N/A	-$2.6M	N/A	-$2.4M+40.8%	-$4.0M-80.0%	-$2.2M-56.3%	-$1.4M
Interest Expense	$111K	N/A	$0	N/A	$5K	$0	$0	N/A
Income Tax	$0	N/A	$0	N/A	$0	$0	$0	$0
Net Income	-$3.1M	N/A	-$2.4M	N/A	-$2.3M+42.3%	-$4.0M-79.7%	-$2.2M-8.7%	-$2.1M
EPS (Diluted)	$-3.97	N/A	$-0.83	N/A	N/A	N/A	N/A	N/A

ARTL Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY19	FY18
Total Assets	$4.7M-64.0%	$13.0M-36.1%	$20.4M-27.7%	$28.3M+335.8%	$6.5M+1532.9%	$397K
Current Assets	$2.6M-76.7%	$11.0M-40.1%	$18.3M-25.5%	$24.6M+453.9%	$4.4M+1020.6%	$396K
Cash & Equivalents	$2.3M-16.9%	$2.8M-59.1%	$6.9M-43.4%	$12.2M+174.9%	$4.4M+1211.1%	$337K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M+42.6%	$1.3M+26.4%	$1.0M-5.8%	$1.1M+6.0%	$1.0M+92.3%	$532K
Current Liabilities	$1.8M+37.3%	$1.3M+29.4%	$998K-2.8%	$1.0M+0.5%	$1.0M+92.0%	$532K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.9M-75.7%	$11.8M-39.4%	$19.4M-28.6%	$27.2M+397.6%	$5.5M+4145.2%	-$135K
Retained Earnings	-$50.1M-24.4%	-$40.3M-29.9%	-$31.0M-48.2%	-$20.9M-335.2%	-$4.8M-82.3%	-$2.6M

Metric	Q3'25	Q4'23	Q3'24	Q4'22	Q3'23	Q4'21	Q3'22	Q1'22
Total Assets	$4.3M-67.3%	$13.0M-15.8%	$15.5M-24.1%	$20.4M-8.9%	$22.4M-20.7%	$28.3M+123.6%	$12.6M+32.5%	$9.5M
Current Assets	$1.8M-83.4%	$11.0M-18.2%	$13.4M-26.7%	$18.3M-9.8%	$20.3M-17.5%	$24.6M+138.5%	$10.3M+37.6%	$7.5M
Cash & Equivalents	$1.7M-38.9%	$2.8M+6.7%	$2.6M-61.7%	$6.9M-3.5%	$7.1M-41.3%	$12.2M+83.5%	$6.6M+14.6%	$5.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.9M+279.6%	$1.3M+40.2%	$921K-9.8%	$1.0M+99.4%	$512K-52.8%	$1.1M+82.8%	$593K-46.3%	$1.1M
Current Liabilities	$4.9M+276.5%	$1.3M+40.2%	$921K-7.7%	$998K+107.9%	$480K-53.3%	$1.0M+95.2%	$526K+8.3%	$486K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$633K-105.4%	$11.8M-19.4%	$14.6M-24.9%	$19.4M-11.4%	$21.9M-19.4%	$27.2M+136.6%	$11.5M+36.1%	$8.4M
Retained Earnings	-$58.8M-46.0%	-$40.3M-8.3%	-$37.2M-20.0%	-$31.0M-12.1%	-$27.7M-32.2%	-$20.9M-23.9%	-$16.9M-55.1%	-$10.9M

ARTL Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY19	FY18
Operating Cash Flow	-$8.3M-1.7%	-$8.2M-2.5%	-$8.0M-30.4%	-$6.1M-119.9%	-$2.8M-73.5%	-$1.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$7.8M+121.5%	$3.5M+18.6%	$3.0M+186.0%	-$3.4M-129.2%	-$1.5M-177496.2%	-$845
Financing Cash Flow	$112K-80.2%	$567K	$0-100.0%	$14.1M+68.5%	$8.4M+503.4%	$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q4'23	Q3'24	Q4'22	Q3'23	Q4'21	Q3'22	Q1'22
Operating Cash Flow	-$3.5M-34.7%	-$2.6M-44.1%	-$1.8M+21.4%	-$2.3M-35.2%	-$1.7M+36.4%	-$2.7M-73.0%	-$1.5M+17.8%	-$1.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$250K-109.1%	$2.7M+249.6%	-$1.8M-202.0%	$1.8M+158.3%	-$3.1M+69.3%	-$10.0M-814.6%	$1.4M+233.1%	-$1.1M
Financing Cash Flow	$3.4M+10662.5%	$32K-94.0%	$535K+299.3%	$134K	$0-100.0%	$18.3M+1043.6%	$1.6M-75.7%	$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ARTL Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY19	FY18
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-209.1%-137.9pp	-71.2%-21.9pp	-49.4%-16.1pp	-33.3%+0.2pp	-33.5%+556.8pp	-590.3%
Current Ratio	1.44-7.1	8.51-9.9	18.36-5.6	23.96+19.6	4.35+3.6	0.75
Debt-to-Equity	0.64+0.5	0.11+0.1	0.05+0.0	0.04-0.1	0.19+4.1	-3.94
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q4'23	Q3'24	Q4'22	Q3'23	Q4'21	Q3'22	Q1'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-73.1%	N/A	-15.8%	N/A	-10.4%+3.9pp	-14.3%+3.5pp	-17.8%+3.9pp	-21.6%
Current Ratio	0.38-8.1	8.51-6.1	14.58-3.8	18.36-23.9	42.30+18.3	23.96+4.3	19.61+4.2	15.44
Debt-to-Equity	-7.74-7.9	0.11+0.0	0.06+0.0	0.05+0.0	0.02-0.0	0.04-0.0	0.05-0.1	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Silo Pharma Inc SILO

$3.9M

TNF Pharmaceuticals TNFA

$9.6M

CERo Therapeutics CERO

$177K

Adial Pharmaceuticals Inc ADIL

$2.8M

Hcw Biologics Inc. HCWB

$2.0M

Frequently Asked Questions

Is Artelo Biosciences Inc profitable?

No, Artelo Biosciences Inc (ARTL) reported a net income of -$9.8M in fiscal year 2024.

What is Artelo Biosciences Inc's earnings per share (EPS)?

Artelo Biosciences Inc (ARTL) reported diluted earnings per share of $-18.30 for fiscal year 2024. This represents a 2.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Artelo Biosciences Inc's operating cash flow?

Artelo Biosciences Inc (ARTL) generated -$8.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Artelo Biosciences Inc's total assets?

Artelo Biosciences Inc (ARTL) had $4.7M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Artelo Biosciences Inc spend on research and development?

Artelo Biosciences Inc (ARTL) invested $6.0M in research and development during fiscal year 2024.

How many shares does Artelo Biosciences Inc have outstanding?

Artelo Biosciences Inc (ARTL) had 567,582 shares outstanding as of fiscal year 2024.

What is Artelo Biosciences Inc's current ratio?

Artelo Biosciences Inc (ARTL) had a current ratio of 1.44 as of fiscal year 2024, which is considered adequate.

What is Artelo Biosciences Inc's debt-to-equity ratio?

Artelo Biosciences Inc (ARTL) had a debt-to-equity ratio of 0.64 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Artelo Biosciences Inc's return on assets (ROA)?

Artelo Biosciences Inc (ARTL) had a return on assets of -209.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Artelo Biosciences Inc's cash runway?

Based on fiscal year 2024 data, Artelo Biosciences Inc (ARTL) had $2.3M in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Artelo Biosciences Inc's Piotroski F-Score?

Artelo Biosciences Inc (ARTL) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Artelo Biosciences Inc's earnings high quality?

Artelo Biosciences Inc (ARTL) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.